Ireland-based UDG Healthcare unit Sharp Packaging Services (Sharp) has expanded its pharmaceutical and clinical packaging capabilities in the US and the UK.
As part of the expansion, Sharp has bought a 146,000ft² foot pharmaceutical packaging facility in Bethlehem, Pennsylvania, US, from Daiichi Sankyo for $14m.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Approved by the US Food and Drug Administration (FDA), the facility has four packaging equipment lines, cold and frozen storage, office space, warehousing and an analytical laboratory.
In the UK, Sharp will invest £9m in a new facility in Rhymney, South Wales, to further grow its clinical packaging business.
Set to be completed by late next year, the initial phase of the expansion will feature the acquisition and renovation of an 110,000ft² facility within the Rhymney site.
Once completed, the new facility will be more than triple the size of the company’s current UK facility.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSharp Packaging Services managing director Mike O’Hara said: “In line with our growth strategy, we are delighted to announce two exciting developments for the Sharp division.
“We continue to add further capacity and scalability to both our commercial and clinical packaging businesses in response to growing demand for our packaging services.”
The company currently provides several contract packaging and clinical services to the pharmaceutical and biotechnology industries.
Sharp’s existing portfolio includes blister packaging, bottling, pouches and stick packs, compliance packaging, formulation and manufacturing services, label design and printing solutions.
